Palisade Bio (PALI) Operating Expenses (2010 - 2026)
Palisade Bio (PALI) posted quarterly Operating Expenses of $10.7 million for Q1 2026, up 365.28% year-over-year from $2.3 million in Q1 2025, and up 7.68% quarter-over-quarter from $10.0 million in Q4 2025.
Palisade Bio (PALI) Operating Expenses (2010 - 2026) Analysis & Trends
Palisade Bio (PALI) has reported Operating Expenses for 17 consecutive years, with $10.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses rose 365.28% year-over-year to $10.7 million; the TTM figure through Mar 2026 stood at $26.5 million (up 96.31% YoY), while the FY2025 annual figure was $18.1 million, up 21.52% from the prior year.
- Operating Expenses improved to $10.7 million in Q1 2026 per PALI's latest filing, from $10.0 million in the prior quarter.
- Across five years, Operating Expenses topped out at $10.7 million in Q1 2026 and bottomed at $2.3 million in Q1 2025.
- Historically, Operating Expenses has averaged $4.3 million across 5 years, with a median of $3.6 million in 2023.
- Annual changes were most pronounced in 2022 — Operating Expenses tumbled 89.13% — and 2026, when it surged 365.28%.
- Palisade Bio's Operating Expenses stood at $3.8 million in 2022, then declined by 18.04% to $3.2 million in 2023, then rose by 7.23% to $3.4 million in 2024, then surged by 195.12% to $10.0 million in 2025, then rose by 7.68% to $10.7 million in 2026.
- Business Quant data shows PALI's Operating Expenses at $10.7 million in Q1 2026, $10.0 million in Q4 2025, and $2.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Palisade Bio | 372.94 Mn | 247.74 Mn | - | 12.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.20 Mn |
| Mar 31, 2026 | 10.75 Mn |
| Dec 31, 2025 | 9.98 Mn |
| Sep 30, 2025 | 2.92 Mn |
| Jun 30, 2025 | 2.84 Mn |
| Mar 31, 2025 | 2.31 Mn |
| Dec 31, 2024 | 3.38 Mn |
| Sep 30, 2024 | 3.59 Mn |
| Jun 30, 2024 | 4.21 Mn |
| Mar 31, 2024 | 3.67 Mn |
| Dec 31, 2023 | 3.15 Mn |
| Sep 30, 2023 | 3.78 Mn |
| Jun 30, 2023 | 3.61 Mn |
| Mar 31, 2023 | 2.78 Mn |
| Dec 31, 2022 | 3.85 Mn |
| Sep 30, 2022 | 4.41 Mn |
| Jun 30, 2022 | 3.57 Mn |
| Mar 31, 2022 | 3.89 Mn |
| Dec 31, 2021 | 4.03 Mn |
| Sep 30, 2021 | 3.02 Mn |